Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared on LinkedIn:
“After neoadjuvant therapy for invasive breast cancer, should a clear margin of less than 1 mm prompt a second operation?
Oprea and colleagues examined this question in a retrospective study published in the World Journal of Surgery. Among 429 patients who underwent breast-conserving surgery and locoregional radiotherapy, 16 (3.7%) developed an invasive recurrence in the treated breast over a median follow-up of 55 months. The median age was 48 years.
Invasive in-breast recurrence by subtype was:
- HR+/HER2− — 6 recurrences (2.8%)
- HR+/HER2+ — 5 recurrences (6.3%)
- HR−/HER2+ — 2 recurrences (4.0%)
- Triple-negative — 3 recurrences (3.7%).
The investigators found no significant association between margin width and invasive recurrence within any subtype. Younger age was the only factor significantly associated with recurrence. With just 2–6 events per subtype, however, the study had limited power to detect a difference.
In UK practice, NICE advises considering re-excision when the radial margin is clear but under 1 mm for invasive cancer, including invasive cancer with associated DCIS. For pure DCIS, the corresponding threshold is 2 mm.
My view is that a clear submillimetre margin deserves discussion. After neoadjuvant therapy, if there is no tumour on ink, imaging and pathology support complete excision, and radiotherapy is planned, these findings give me greater confidence in discussing observation with the patient. The decision to return to theatre should reflect the likelihood of residual disease and what another operation would mean for her.”
Title: Surgical Margin Width Does Not Impact Local Recurrence Across Tumor Subtypes After Neoadjuvant Systemic Treatment and Breast-Conserving Surgery
Authors: Adela-Luciana Oprea, Canan Aral, Yusuf Emre Aytin, Suleyman Bademler, Hasan Karanlik, M. Umit Ugurlu, Atakan Sezer, Tiberiu-Bogdan Szekely, Rares Georgescu, Bahadir M. Gulluoglu.
You can also read:
Can Breast-Conserving Surgery Be Oncologically Safe for Multiple Ipsilateral Breast Cancers?
